Physician profile
Sofia Schedler
NPI 1447829767
$3,177.27
in general payments reported to CMS, 2019-2025
17 companies · $864 in 2025
The $864 reported for 2025 was more than what 89% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $441 · 2022: $781 · 2023: $469 · 2024: $622 · 2025: $864.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,723 · Entertainment: $232.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,722.64 |
| Entertainment | $232.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Vision Care, INC. | $688.24 | 2022-2025 | Acuvue |
| Sun Pharmaceutical Industries INC. | $449.27 | 2022-2025 | Cequa |
| Bausch & Lomb Americas INC. | $433.61 | 2022-2025 | Infuse |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $420.51 | 2021 | |
| Alcon Vision LLC | $307.71 | 2022-2025 | Precision7, Precision 1, Dailies Total1 |
| Optos, INC. | $232.04 | 2024-2025 | Panoramic Ophthalmoscope, Oct Ophthalmoscope, Nfc-700 |
| Glaukos Corporation | $174.66 | 2025 | Photrexa Viscous and Photrexa |
| Biotissue Holdings INC. | $97.74 | 2025 | |
| Tarsus Pharmaceuticals, INC. | $90.30 | 2024-2025 | Xdemvy |
| Coopervision INC. | $77.15 | 2024-2025 | Myday Contact Lens |
| Abbvie INC. | $50.47 | 2022-2024 | |
| Oyster Point Pharma, INC. | $31.73 | 2022-2024 | Tyrvaya |
| Dompe US, INC. | $29.99 | 2025 | Oxervate |
| Spark Therapeutics, INC. | $27.83 | 2022 | |
| Horizon Therapeutics Plc | $22.55 | 2023 | Tepezza |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $22.51 | 2022 | |
| Kala Pharmaceuticals, INC. | $20.96 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sofia Schedler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.